Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease ( The Yates Network ) True North Therapeutics announced a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia. The article entitled 'TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient ...
April 14, 2014 - EurekAlert!